FWM
VTVT icon

Focused Wealth Management’s vTv Therapeutics VTVT Stock Holding History

Focused Wealth Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-250
Closed -$2.88K – 964
2023
Q4 		$2.88K Hold
250
– – ﹤0.01% 730
2023
Q3 		$4.78K Hold
250
– – ﹤0.01% 649
2023
Q2 		$7.4K Hold
250
– – ﹤0.01% 604
2023
Q1 		$8.08K Buy
250
+125
+100% +$4.24K ﹤0.01% 577
2022
Q4 		$3.31K Hold
125
– – ﹤0.01% 727
2022
Q3 		$5K Buy
+125
New +$4.92K ﹤0.01% 639

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCMC
Planning Capital Management Corporation Paoli, Pennsylvania $151M AUM 30.62% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Focused Wealth Management's VTVT Position: Q1 2024 in Review

Focused Wealth Management sold out of vTv Therapeutics (VTVT) in Q1 2024, closing a stake of 250 shares — an estimated $2.88K sold.

Focused Wealth Management first reported a position in VTVT in Q3 2022 and held it in 6 quarters. The position peaked at $8.08K in Q1 2023. 19 funds tracked by Wall St. Rank hold VTVT as of Q1 2024.

  • Focused Wealth Management reported no remaining vTv Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 250 vTv Therapeutics shares in Q1 2024, an estimated $2.88K.
  • Focused Wealth Management first reported a position in vTv Therapeutics in Q3 2022 and held it in 6 quarters.
  • Focused Wealth Management's vTv Therapeutics position peaked at $8.08K in Q1 2023.
  • 19 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.